Breaking News Instant updates and real-time market news.

RKLY

Rockley Photonics

/

+

09:06
10/25/22
10/25
09:06
10/25/22
09:06

Rockley Photonics announces $90.6M private placement of convertible notes

Rockley Photonics announced that it has entered into a definitive agreement with holders of outstanding Convertible Senior Secured Notes due 2026 and one new investor to issue approximately $90.6M aggregate original principal amount of a new series of Convertible Senior Secured Notes due 2026 generating net proceeds after discount of approximately $89.4M with an initial conversion price of $0.6888 and warrants to purchase 131.6 million ordinary shares of the Company at a price of $1.1182 per share, subject to certain anti-dilution adjustments.

OTHER BREAKING NEWS FROM THE FLY

Downgrade
Salesforce downgraded to Peer Perform from Outperform at Wolfe Research » 20:41
12/01/22
12/01
20:41
12/01/22
20:41
CRM

Salesforce

$146.99 /

-13.01 (-8.13%)

Wolfe Research analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CRM Salesforce
$146.99 /

-13.01 (-8.13%)

CRM Salesforce
$146.99 /

-13.01 (-8.13%)

08:55 Today Jefferies
Salesforce price target lowered to $230 from $240 at Jefferies
08:23 Today BofA
Salesforce price target lowered to $200 from $210 at BofA
08:17 Today RBC Capital
Salesforce price target lowered to $200 from $235 at RBC Capital
08:01 Today BMO Capital
Salesforce price target lowered to $172 from $180 at BMO Capital
CRM Salesforce
$146.99 /

-13.01 (-8.13%)

CRM Salesforce
$146.99 /

-13.01 (-8.13%)

CRM Salesforce
$146.99 /

-13.01 (-8.13%)

CRM Salesforce
$146.99 /

-13.01 (-8.13%)

Upgrade
Toronto-Dominion upgraded to Buy from Hold at Canaccord » 20:40
12/01/22
12/01
20:40
12/01/22
20:40
TD

Toronto-Dominion

$68.36 /

+1.66 (+2.49%)

Canaccord analyst Scott…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
TD Toronto-Dominion
$68.36 /

+1.66 (+2.49%)

TD Toronto-Dominion
$68.36 /

+1.66 (+2.49%)

11/22/22 Scotiabank
Toronto-Dominion price target lowered to C$100 from C$101 at Scotiabank
11/18/22 National Bank
Toronto-Dominion price target lowered to C$103 from C$106 at National Bank
09/02/22 Keefe Bruyette
Toronto-Dominion upgraded to Outperform from Market Perform at Keefe Bruyette
08/26/22 Canaccord
Toronto-Dominion price target lowered to C$94.50 from C$96 at Canaccord
TD Toronto-Dominion
$68.36 /

+1.66 (+2.49%)

TD Toronto-Dominion
$68.36 /

+1.66 (+2.49%)

TD Toronto-Dominion
$68.36 /

+1.66 (+2.49%)

TD Toronto-Dominion
$68.36 /

+1.66 (+2.49%)

Hot Stocks
Accenture acquires Fiftyfive5 » 20:34
12/01/22
12/01
20:34
12/01/22
20:34
ACN

Accenture

$302.65 /

+1.98 (+0.66%)

The company states:…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ACN Accenture
$302.65 /

+1.98 (+0.66%)

ACN Accenture
$302.65 /

+1.98 (+0.66%)

10/14/22 JPMorgan
Accenture price target lowered to $306 from $329 at JPMorgan
10/13/22 Wells Fargo
Wells sees some encouraging signs from emerging metaverse app economy
09/27/22 Alliance Global Partners
Perficient upgraded to Buy from Neutral at Alliance Global Partners
09/26/22 Barclays
Accenture price target lowered to $340 from $370 at Barclays
ACN Accenture
$302.65 /

+1.98 (+0.66%)

ACN Accenture
$302.65 /

+1.98 (+0.66%)

ACN Accenture
$302.65 /

+1.98 (+0.66%)

Hot Stocks
Anavex phase 2B/3 study of blarcamesine met primary and key secondary endpoints » 20:30
12/01/22
12/01
20:30
12/01/22
20:30
AVXL

Anavex

$8.85 /

+0.03 (+0.34%)

Anavex Life Sciences…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AVXL Anavex
$8.85 /

+0.03 (+0.34%)

AVXL Anavex
$8.85 /

+0.03 (+0.34%)

06/23/22 Berenberg
Anavex initiated with a Buy at Berenberg
02/02/22 Cantor Fitzgerald
Anavex price target lowered to $16 from $27 at Cantor Fitzgerald
AVXL Anavex
$8.85 /

+0.03 (+0.34%)

AVXL Anavex
$8.85 /

+0.03 (+0.34%)

AVXL Anavex
$8.85 /

+0.03 (+0.34%)

Downgrade
Wolfe Research cuts Edwards Lifesciences to Peer Perform on macro, TAVR maturity » 19:51
12/01/22
12/01
19:51
12/01/22
19:51
EW

Edwards Lifesciences

$77.50 /

+0.28 (+0.36%)

, ABT

Abbott

$107.96 /

+0.46 (+0.43%)

, BSX

Boston Scientific

$46.16 /

+0.87 (+1.92%)

Wolfe Research analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
EW Edwards Lifesciences
$77.50 /

+0.28 (+0.36%)

ABT Abbott
$107.96 /

+0.46 (+0.43%)

BSX Boston Scientific
$46.16 /

+0.87 (+1.92%)

EW Edwards Lifesciences
$77.50 /

+0.28 (+0.36%)

16:59 Today Wolfe Research
Edwards Lifesciences downgraded to Peer Perform from Outperform at Wolfe Research
11/28/22 RBC Capital
Edwards Lifesciences price target lowered to $105 from $118 at RBC Capital
11/16/22 Evercore ISI
Evercore ISI removes seven Healthcare Services and Tech stocks from 'TAP' list
10/28/22 Cowen
Edwards Lifesciences price target lowered to $100 from $125 at Cowen
ABT Abbott
$107.96 /

+0.46 (+0.43%)

11/16/22 Evercore ISI
Evercore ISI removes seven Healthcare Services and Tech stocks from 'TAP' list
10/26/22 Mizuho
Abbott initiated with a Neutral at Mizuho
10/21/22 Barclays
Abbott post-earnings selloff seems overdone, says Barclays
10/20/22 RBC Capital
Abbott price target lowered to $126 from $132 at RBC Capital
BSX Boston Scientific
$46.16 /

+0.87 (+1.92%)

11/30/22 Lake Street
Apollo Endosurgery downgraded to Hold from Buy at Lake Street
11/29/22 Piper Sandler
Piper says Apollo Endosurgery can help Boston Scientific expand ELS franchise
11/29/22 Craig-Hallum
Craig-Hallum sees potential for competing Apollo Endosurgery bids
11/01/22 Piper Sandler
Abiomed downgraded to Neutral from Overweight at Piper Sandler
EW Edwards Lifesciences
$77.50 /

+0.28 (+0.36%)

ABT Abbott
$107.96 /

+0.46 (+0.43%)

BSX Boston Scientific
$46.16 /

+0.87 (+1.92%)

ABT Abbott
$107.96 /

+0.46 (+0.43%)

EW Edwards Lifesciences
$77.50 /

+0.28 (+0.36%)

ABT Abbott
$107.96 /

+0.46 (+0.43%)

BSX Boston Scientific
$46.16 /

+0.87 (+1.92%)

EW Edwards Lifesciences
$77.50 /

+0.28 (+0.36%)

ABT Abbott
$107.96 /

+0.46 (+0.43%)

BSX Boston Scientific
$46.16 /

+0.87 (+1.92%)

Hot Stocks
OceanTech Acquisitions I announces stockholder approval to extend combination » 19:23
12/01/22
12/01
19:23
12/01/22
19:23
OTEC

OceanTech Acquisitions I

$10.32 /

+0.06 (+0.58%)

OceanTech Acquisitions…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
OTEC OceanTech Acquisitions I
$10.32 /

+0.06 (+0.58%)

Downgrade
Americanas SA downgraded to Sell from Neutral at Goldman Sachs » 19:20
12/01/22
12/01
19:20
12/01/22
19:20
BZWHF

Americanas SA

$22.75 /

+ (+0.00%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BZWHF Americanas SA
$22.75 /

+ (+0.00%)

11/11/22 Itau BBA
Americanas SA downgraded to Market Perform from Outperform at Itau BBA
11/09/22 JPMorgan
Americanas SA downgraded to Underweight from Neutral at JPMorgan
Downgrade
Magazine Luiza downgraded to Neutral from Buy at Goldman Sachs » 19:18
12/01/22
12/01
19:18
12/01/22
19:18
MGLUY

Magazine Luiza

$2.80 /

+ (+0.00%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
MGLUY Magazine Luiza
$2.80 /

+ (+0.00%)

12/23/21 Citi
Magazine Luiza initiated with a Neutral at Citi
Hot Stocks
Equinix CFO sells $1.75M in common stock » 19:10
12/01/22
12/01
19:10
12/01/22
19:10
EQIX

Equinix

$698.10 /

+7.95 (+1.15%)

In a regulatory filing,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
EQIX Equinix
$698.10 /

+7.95 (+1.15%)

EQIX Equinix
$698.10 /

+7.95 (+1.15%)

11/17/22 Deutsche Bank
Equinix price target raised to $680 from $635 at Deutsche Bank
11/14/22 RBC Capital
Equinix price target raised to $720 from $668 at RBC Capital
11/13/22 Citi
Equinix price target lowered to $750 from $810 at Citi
11/03/22 Credit Suisse
Equinix price target raised to $591 from $571 at Credit Suisse
EQIX Equinix
$698.10 /

+7.95 (+1.15%)

EQIX Equinix
$698.10 /

+7.95 (+1.15%)

EQIX Equinix
$698.10 /

+7.95 (+1.15%)

EQIX Equinix
$698.10 /

+7.95 (+1.15%)

Initiation
Amprius Technologies initiated with a Buy at B. Riley » 19:00
12/01/22
12/01
19:00
12/01/22
19:00
AMPX

Amprius Technologies

$10.14 /

-0.19 (-1.84%)

B. Riley analyst…

B. Riley analyst Christopher Souther initiated coverage of Amprius Technologies with a Buy rating and $14 price target.

ShowHide Related Items >><<
AMPX Amprius Technologies
$10.14 /

-0.19 (-1.84%)

AMPX Amprius Technologies
$10.14 /

-0.19 (-1.84%)

10/27/22 EF Hutton
Amprius Technologies initiated with a Buy at EF Hutton
10/13/22 Oppenheimer
Amprius Technologies initiated with an Outperform at Oppenheimer
AMPX Amprius Technologies
$10.14 /

-0.19 (-1.84%)

AMPX Amprius Technologies
$10.14 /

-0.19 (-1.84%)

Initiation
Enovix initiated with a Buy at B. Riley » 19:00
12/01/22
12/01
19:00
12/01/22
19:00
ENVX

Enovix

$12.28 /

-0.7 (-5.39%)

B. Riley analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ENVX Enovix
$12.28 /

-0.7 (-5.39%)

ENVX Enovix
$12.28 /

-0.7 (-5.39%)

11/04/22 Janney Montgomery Scott
Janney starts Enovix with Buy after earnings sellofff
11/04/22 Janney Montgomery Scott
Enovix initiated with a Buy at Janney Montgomery Scott
11/02/22 Cowen
Enovix price target lowered to $25 from $36 at Cowen
10/27/22 EF Hutton
Enovix initiated with a Buy at EF Hutton
ENVX Enovix
$12.28 /

-0.7 (-5.39%)

ENVX Enovix
$12.28 /

-0.7 (-5.39%)

ENVX Enovix
$12.28 /

-0.7 (-5.39%)

Hot Stocks
Theratechnologies trading resumes  19:00
12/01/22
12/01
19:00
12/01/22
19:00
THTX

Theratechnologies

$2.11 /

-0.1 (-4.52%)

 
ShowHide Related Items >><<
THTX Theratechnologies
$2.11 /

-0.1 (-4.52%)

THTX Theratechnologies
$2.11 /

-0.1 (-4.52%)

11/30/22 JonesTrading
Theratechnologies initiated with a Buy at JonesTrading
11/17/22 Cantor Fitzgerald
Theratechnologies initiated with an Overweight at Cantor Fitzgerald
07/15/22 National Bank
Theratechnologies price target lowered to C$3.25 from C$3.75 at National Bank
THTX Theratechnologies
$2.11 /

-0.1 (-4.52%)

THTX Theratechnologies
$2.11 /

-0.1 (-4.52%)

Hot Stocks
Babcock & Wilcox and Chart Industries to collaborate on hydrogen generation » 18:48
12/01/22
12/01
18:48
12/01/22
18:48
BW

Babcock & Wilcox

$5.11 /

+0.52 (+11.34%)

, GTLS

Chart Industries

$137.34 /

-5.51 (-3.86%)

Babcock & Wilcox (BW)…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GTLS Chart Industries
$137.34 /

-5.51 (-3.86%)

BW Babcock & Wilcox
$5.11 /

+0.52 (+11.34%)

BW Babcock & Wilcox
$5.11 /

+0.52 (+11.34%)

10/28/22 B. Riley
Babcock & Wilcox price target lowered to $8 from $12.50 at B. Riley
07/19/22 Craig-Hallum
Babcock & Wilcox initiated with a Buy at Craig-Hallum
GTLS Chart Industries
$137.34 /

-5.51 (-3.86%)

11/29/22 Citi
Halliburton should take equity stake in Chart Industries, says Citi
11/22/22 Goldman Sachs
Chart Industries downgraded to Neutral from Buy at Goldman Sachs
11/18/22 Piper Sandler
Chart Industries downgraded on higher leverage at Piper Sandler
11/18/22 Piper Sandler
Chart Industries downgraded to Neutral from Overweight at Piper Sandler
GTLS Chart Industries
$137.34 /

-5.51 (-3.86%)

BW Babcock & Wilcox
$5.11 /

+0.52 (+11.34%)

GTLS Chart Industries
$137.34 /

-5.51 (-3.86%)

Hot Stocks
Live Nation director Iovine acquires 13,740 common shares » 18:45
12/01/22
12/01
18:45
12/01/22
18:45
LYV

Live Nation

$73.55 /

+0.8 (+1.10%)

In a regulatory filing,…

In a regulatory filing, Live Nation Entertainment director Jimmy Iovine disclosed the purchase of 13,740 common shares of the company on December 1 at a price of $73.28 per share.

ShowHide Related Items >><<
LYV Live Nation
$73.55 /

+0.8 (+1.10%)

LYV Live Nation
$73.55 /

+0.8 (+1.10%)

11/30/22 Morgan Stanley
Live Nation price target lowered to $80 from $95 at Morgan Stanley
11/28/22 Citi
Live Nation upgraded to Buy from Neutral at Citi
11/22/22 Redburn
Redburn starts Live Nation with a Neutral
11/22/22 Redburn
Live Nation initiated with a Neutral at Redburn
LYV Live Nation
$73.55 /

+0.8 (+1.10%)

LYV Live Nation
$73.55 /

+0.8 (+1.10%)

LYV Live Nation
$73.55 /

+0.8 (+1.10%)

LYV Live Nation
$73.55 /

+0.8 (+1.10%)

Earnings
Netgear sees FY23 revenue up low to mid-single digits, consensus $985.01M » 18:41
12/01/22
12/01
18:41
12/01/22
18:41
NTGR

Netgear

$20.16 /

+0.54 (+2.75%)

Says expects to be able…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
NTGR Netgear
$20.16 /

+0.54 (+2.75%)

NTGR Netgear
$20.16 /

+0.54 (+2.75%)

07/28/22 BWS Financial
Netgear upgraded to Buy from Neutral at BWS Financial
04/28/22 Deutsche Bank
Netgear price target lowered to $22 from $25 at Deutsche Bank
04/19/22 Cowen
Netgear's Q1 miss suggests challenges to persist, says Cowen
04/18/22 BWS Financial
Netgear price target lowered to $27 from $30 at BWS Financial
NTGR Netgear
$20.16 /

+0.54 (+2.75%)

NTGR Netgear
$20.16 /

+0.54 (+2.75%)

Hot Stocks
Theratechnologies announces update from TH1902 study » 18:32
12/01/22
12/01
18:32
12/01/22
18:32
THTX

Theratechnologies

$2.11 /

-0.1 (-4.52%)

Theratechnologies…

Theratechnologies "announced that it has decided to pause the enrollment of patients in its Phase 1 clinical trial of TH1902, the Company's lead investigational peptide drug conjugate for the treatment of sortilin-expressing cancers. The Company plans to submit an amendment to its protocol to the U.S. Food and Drug Administration for approval. Theratechnologies voluntarily made the decision to pause enrollment and revisit the study design after consulting with its investigators. Efficacy results observed thus far were not convincing enough to pursue enrolling patients and did not outweigh the adverse events seen in some patients. As previously reported, these adverse events consist mainly of neuropathy and eye toxicity."

ShowHide Related Items >><<
THTX Theratechnologies
$2.11 /

-0.1 (-4.52%)

THTX Theratechnologies
$2.11 /

-0.1 (-4.52%)

11/30/22 JonesTrading
Theratechnologies initiated with a Buy at JonesTrading
11/17/22 Cantor Fitzgerald
Theratechnologies initiated with an Overweight at Cantor Fitzgerald
07/15/22 National Bank
Theratechnologies price target lowered to C$3.25 from C$3.75 at National Bank
THTX Theratechnologies
$2.11 /

-0.1 (-4.52%)

THTX Theratechnologies
$2.11 /

-0.1 (-4.52%)

Hot Stocks
Theratechnologies trading halted, news pending  18:28
12/01/22
12/01
18:28
12/01/22
18:28
THTX

Theratechnologies

$2.11 /

-0.1 (-4.52%)

 
ShowHide Related Items >><<
THTX Theratechnologies
$2.11 /

-0.1 (-4.52%)

THTX Theratechnologies
$2.11 /

-0.1 (-4.52%)

11/30/22 JonesTrading
Theratechnologies initiated with a Buy at JonesTrading
11/17/22 Cantor Fitzgerald
Theratechnologies initiated with an Overweight at Cantor Fitzgerald
07/15/22 National Bank
Theratechnologies price target lowered to C$3.25 from C$3.75 at National Bank
THTX Theratechnologies
$2.11 /

-0.1 (-4.52%)

THTX Theratechnologies
$2.11 /

-0.1 (-4.52%)

Hot Stocks
Crowdstrike CEO: Most companies would kill for our results » 18:24
12/01/22
12/01
18:24
12/01/22
18:24
CRWD

Crowdstrike

$124.06 /

+6.49 (+5.52%)

In an interview on…

In an interview on CNBC's Mad Money, George Kurtz said customers are embracing Crowdstrike and want to buy more of its products, especially at the enterprise level. Net retention rates are near all-time highs, he noted. Lots of SMB customers are in "wait and see mode" with interest rates rising, Kurtz added. They are putting purchases on hold resulting in "elongated sales cycles."

ShowHide Related Items >><<
CRWD Crowdstrike
$124.06 /

+6.49 (+5.52%)

CRWD Crowdstrike
$124.06 /

+6.49 (+5.52%)

06:55 Today Redburn
Crowdstrike initiated with a Buy at Redburn
05:52 Today Wolfe Research
Crowdstrike downgraded to Peer Perform from Outperform at Wolfe Research
11/30/22 Truist
Crowdstrike price target lowered to $200 from $275 at Truist
11/30/22 RBC Capital
Crowdstrike price target lowered to $165 from $200 at RBC Capital
CRWD Crowdstrike
$124.06 /

+6.49 (+5.52%)

CRWD Crowdstrike
$124.06 /

+6.49 (+5.52%)

CRWD Crowdstrike
$124.06 /

+6.49 (+5.52%)

CRWD Crowdstrike
$124.06 /

+6.49 (+5.52%)

On The Fly
Fly Intel: After-Hours Movers » 18:24
12/01/22
12/01
18:24
12/01/22
18:24
IOT

Samsara

$9.91 /

+0.39 (+4.10%)

, SMAR

Smartsheet

$32.55 /

+1.83 (+5.96%)

, PATH

UiPath

$12.95 /

+0.47 (+3.77%)

, TLYS

Tilly's

$8.82 /

-0.67 (-7.06%)

, PD

PagerDuty

$22.54 /

+0.27 (+1.21%)

, SOL

ReneSola

$4.55 /

-0.16 (-3.40%)

, ASAN

Asana

$18.07 /

-0.09 (-0.50%)

, ZS

Zscaler

$144.55 /

+11.09 (+8.31%)

, MRVL

Marvell

$45.38 /

-1.175 (-2.52%)

, VEEV

Veeva

$191.50 /

+1.27 (+0.67%)

, ZUMZ

Zumiez

$21.80 /

-1.46 (-6.28%)

, CHPT

ChargePoint

$12.20 /

-0.205 (-1.65%)

, AMBA

Ambarella

$73.80 /

-0.33 (-0.45%)

Check out this evening's…

ShowHide Related Items >><<
ZUMZ Zumiez
$21.80 /

-1.46 (-6.28%)

ZS Zscaler
$144.55 /

+11.09 (+8.31%)

VEEV Veeva
$191.50 /

+1.27 (+0.67%)

TLYS Tilly's
$8.82 /

-0.67 (-7.06%)

SOL ReneSola
$4.55 /

-0.16 (-3.40%)

SMAR Smartsheet
$32.55 /

+1.83 (+5.96%)

PD PagerDuty
$22.54 /

+0.27 (+1.21%)

PATH UiPath
$12.95 /

+0.47 (+3.77%)

MRVL Marvell
$45.38 /

-1.175 (-2.52%)

IOT Samsara
$9.91 /

+0.39 (+4.10%)

CHPT ChargePoint
$12.20 /

-0.205 (-1.65%)

ASAN Asana
$18.07 /

-0.09 (-0.50%)

AMBA Ambarella
$73.80 /

-0.33 (-0.45%)

IOT Samsara
$9.91 /

+0.39 (+4.10%)

09/22/22 MoffettNathanson
Samsara initiated with a Buy at MoffettNathanson
06/27/22 Goldman Sachs
Samsara downgraded to Neutral from Buy at Goldman Sachs
06/16/22 Goldman Sachs
Goldman left Samsara analyst day with stronger conviction
05/31/22 RBC Capital
Samsara price target lowered to $18 from $28 at RBC Capital
SMAR Smartsheet
$32.55 /

+1.83 (+5.96%)

10/13/22 KeyBanc
KeyBanc bullish on Smartsheet, initiates with an Overweight
10/13/22 KeyBanc
Smartsheet initiated with an Overweight at KeyBanc
10/03/22 Morgan Stanley
Smartsheet price target lowered to $54 from $62 at Morgan Stanley
09/26/22 RBC Capital
RBC Capital positive on Smartsheet positioning, mixed on spending
PATH UiPath
$12.95 /

+0.47 (+3.77%)

11/03/22 Oppenheimer
UiPath downgraded to Perform from Outperform at Oppenheimer
10/18/22 Barclays
UiPath downgraded to Equal Weight on 'digestive phase' at Barclays
10/18/22 Barclays
UiPath downgraded to Equal Weight from Overweight at Barclays
09/30/22 Canaccord
UiPath price target lowered to $14 from $15 at Canaccord
TLYS Tilly's
$8.82 /

-0.67 (-7.06%)

09/06/22 B. Riley
Tilly's price target lowered to $10 from $12 at B. Riley
09/02/22 Seaport Global
Seaport downgrades Tilly's with shares 'no longer cheap' after miss
09/02/22 Seaport Global
Tilly's downgraded to Neutral from Buy at Seaport Global
09/02/22 Roth Capital
Tilly's price target lowered to $9 from $10 at Roth Capital
PD PagerDuty
$22.54 /

+0.27 (+1.21%)

10/26/22 Truist
PagerDuty price target lowered to $30 from $35 at Truist
09/23/22 Credit Suisse
PagerDuty initiated with an Outperform at Credit Suisse
09/02/22 Craig-Hallum
PagerDuty price target lowered to $34 from $37 at Craig-Hallum
09/02/22 Cowen
PagerDuty price target lowered to $37 from $40 at Cowen
SOL ReneSola
$4.55 /

-0.16 (-3.40%)

15:26 Today Roth Capital
U.S. to announce 'affirmative' finding in solar trade case, says Roth Capital
11/10/22 Morgan Stanley
New California 'NEM 3.0' proposal 'screens positive,' says Morgan Stanley
09/13/22 Northland
Northland starts ReneSola at Outperform on tailwinds in U.S. and Europe
09/13/22 Northland
ReneSola initiated with an Outperform at Northland
ASAN Asana
$18.07 /

-0.09 (-0.50%)

11/28/22 JPMorgan
Asana price target lowered to $19 from $22 at JPMorgan
10/20/22 Piper Sandler
Asana price target lowered to $24 from $28 at Piper Sandler
10/13/22 KeyBanc
Asana initiated with a Sector Weight at KeyBanc
10/03/22 Morgan Stanley
Asana price target lowered to $28 from $35 at Morgan Stanley
ZS Zscaler
$144.55 /

+11.09 (+8.31%)

06:59 Today Redburn
Zscaler initiated with a Neutral at Redburn
11/28/22 MKM Partners
Zscaler price target lowered to $190 from $225 at MKM Partners
11/22/22 Morgan Stanley
Zscaler price target lowered to $180 from $225 at Morgan Stanley
11/22/22 Barclays
Zscaler price target lowered to $160 from $175 at Barclays
MRVL Marvell
$45.38 /

-1.175 (-2.52%)

11/28/22 JPMorgan
Marvell price target lowered to $75 from $85 at JPMorgan
11/28/22 Oppenheimer
Marvell price target lowered to $80 from $90 at Oppenheimer
11/15/22 Credit Suisse
Marvell initiated with an Outperform at Credit Suisse
10/27/22 Jefferies
Meta commentary positive for datacenter semi names, says Jefferies
VEEV Veeva
$191.50 /

+1.27 (+0.67%)

11/01/22 Oppenheimer
Merck pact shows Veeva life science vendor of choice, says Oppenheimer
10/31/22 Baird
Veeva price target lowered to $233 from $250 at Baird
10/31/22 Wells Fargo
Veeva initiated with an Equal Weight at Wells Fargo
10/20/22 Piper Sandler
Veeva price target lowered to $220 from $245 at Piper Sandler
ZUMZ Zumiez
$21.80 /

-1.46 (-6.28%)

09/09/22 B. Riley
Zumiez downgraded to Neutral after 'substantial' miss at B. Riley
09/09/22 William Blair
William Blair downgrades Zumiez on 'sluggish' sales trends
09/09/22 William Blair
Zumiez downgraded to Market Perform from Outperform at William Blair
09/09/22 B. Riley
Zumiez downgraded to Neutral from Buy at B. Riley
CHPT ChargePoint
$12.20 /

-0.205 (-1.65%)

11/29/22 Citi
ChargePoint price target lowered to $14 from $15.50 at Citi
11/07/22 B. Riley
ChargePoint price target lowered to $18 from $20 at B. Riley
09/07/22 Credit Suisse
ChargePoint initiated with an Outperform at Credit Suisse
08/31/22 Oppenheimer
ChargePoint results strong despite supply headwinds, says Oppenheimer
AMBA Ambarella
$73.80 /

-0.33 (-0.45%)

11/21/22 Jefferies
Ambarella price target lowered to $96 from $104 at Jefferies
11/21/22 Stifel
Ambarella price target raised to $90 from $76 at Stifel
11/18/22 Wells Fargo
Ambarella's CV3 win a 'significant endorsement,' says Wells Fargo
10/18/22 Deutsche Bank
Ambarella price target lowered to $62 from $75 at Deutsche Bank
ZUMZ Zumiez
$21.80 /

-1.46 (-6.28%)

ZS Zscaler
$144.55 /

+11.09 (+8.31%)

VEEV Veeva
$191.50 /

+1.27 (+0.67%)

TLYS Tilly's
$8.82 /

-0.67 (-7.06%)

SOL ReneSola
$4.55 /

-0.16 (-3.40%)

SMAR Smartsheet
$32.55 /

+1.83 (+5.96%)

PD PagerDuty
$22.54 /

+0.27 (+1.21%)

PATH UiPath
$12.95 /

+0.47 (+3.77%)

MRVL Marvell
$45.38 /

-1.175 (-2.52%)

IOT Samsara
$9.91 /

+0.39 (+4.10%)

CHPT ChargePoint
$12.20 /

-0.205 (-1.65%)

ASAN Asana
$18.07 /

-0.09 (-0.50%)

AMBA Ambarella
$73.80 /

-0.33 (-0.45%)

  • 15
    Dec
SOL ReneSola
$4.55 /

-0.16 (-3.40%)

MRVL Marvell
$45.38 /

-1.175 (-2.52%)

CHPT ChargePoint
$12.20 /

-0.205 (-1.65%)

ZUMZ Zumiez
$21.80 /

-1.46 (-6.28%)

ZS Zscaler
$144.55 /

+11.09 (+8.31%)

VEEV Veeva
$191.50 /

+1.27 (+0.67%)

TLYS Tilly's
$8.82 /

-0.67 (-7.06%)

SOL ReneSola
$4.55 /

-0.16 (-3.40%)

SMAR Smartsheet
$32.55 /

+1.83 (+5.96%)

PD PagerDuty
$22.54 /

+0.27 (+1.21%)

PATH UiPath
$12.95 /

+0.47 (+3.77%)

MRVL Marvell
$45.38 /

-1.175 (-2.52%)

CHPT ChargePoint
$12.20 /

-0.205 (-1.65%)

ASAN Asana
$18.07 /

-0.09 (-0.50%)

AMBA Ambarella
$73.80 /

-0.33 (-0.45%)

ZS Zscaler
$144.55 /

+11.09 (+8.31%)

VEEV Veeva
$191.50 /

+1.27 (+0.67%)

SOL ReneSola
$4.55 /

-0.16 (-3.40%)

SMAR Smartsheet
$32.55 /

+1.83 (+5.96%)

PD PagerDuty
$22.54 /

+0.27 (+1.21%)

PATH UiPath
$12.95 /

+0.47 (+3.77%)

MRVL Marvell
$45.38 /

-1.175 (-2.52%)

IOT Samsara
$9.91 /

+0.39 (+4.10%)

CHPT ChargePoint
$12.20 /

-0.205 (-1.65%)

ASAN Asana
$18.07 /

-0.09 (-0.50%)

AMBA Ambarella
$73.80 /

-0.33 (-0.45%)

Hot Stocks
Ivanhoe Electric exec chairman Friedland acquires 422,767 common shares » 18:22
12/01/22
12/01
18:22
12/01/22
18:22
IE

Ivanhoe Electric

$10.20 /

-0.23 (-2.21%)

In a regulatory filing,…

In a regulatory filing, Ivanhoe Electric executive chairman Robert Friedland disclosed the purchase of 422,767 common shares of the company on November 29 at a price of $9.85 per share.

ShowHide Related Items >><<
IE Ivanhoe Electric
$10.20 /

-0.23 (-2.21%)

IE Ivanhoe Electric
$10.20 /

-0.23 (-2.21%)

09/28/22 Raymond James
Ivanhoe Electric initiated with an Outperform at Raymond James
08/18/22 JPMorgan
Ivanhoe Electric initiated with a Neutral at JPMorgan
07/25/22 Jefferies
Ivanhoe Electric initiated with a Buy at Jefferies
07/25/22 BMO Capital
Ivanhoe Electric initiated with an Outperform at BMO Capital
  • 28
    Jun
IE Ivanhoe Electric
$10.20 /

-0.23 (-2.21%)

Hot Stocks
Morningstar chairman sells $2.0M in common stock » 17:59
12/01/22
12/01
17:59
12/01/22
17:59
MORN

Morningstar

$249.76 /

+4.18 (+1.70%)

In a regulatory filing,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MORN Morningstar
$249.76 /

+4.18 (+1.70%)

09/20/22 Redburn
Morningstar upgraded to Buy at Redburn on downturn resilience
09/20/22 Redburn
Morningstar upgraded to Buy from Neutral at Redburn
MORN Morningstar
$249.76 /

+4.18 (+1.70%)

Hot Stocks
Y-mAbs Therapeutics: FDA issues CRL for BLA for omburtamab » 17:37
12/01/22
12/01
17:37
12/01/22
17:37
YMAB

Y-mAbs Therapeutics

$4.50 /

+0.05 (+1.12%)

Y-mAbs Therapeutics…

Y-mAbs Therapeutics announced that the U.S. FDA has issued a complete response letter for the Biologics License Application for the investigational medicine I-omburtamab for the treatment of CNS/leptomeningeal metastasis from neuroblastoma. The letter indicates that the FDA completed the review of the application and determined that it is unable to approve the BLA in its current form. This is consistent with the outcome of the Oncologic Drugs Advisory Committee Meeting in October. The CRL includes a recommendation for meeting with the agency to discuss adequate and well-controlled trial design to demonstrate substantial evidence of effectiveness and a favorable benefit-risk profile. Y-mAbs is assessing the implications of the CRL and its plans for the omburtamab program. "We are disappointed by the CRL but not surprised based on the outcome of the ODAC meeting on October 28. We want to express our gratitude to all the patients, their families, and investigators who have participated in our clinical trials and advocated for the advancement of omburtamab," said Thomas Gad, President, and Interim CEO. "While we evaluate the implications of the CRL for the future of omburtamab, we are excited about refining our focus primarily to drive growth from DANYELZA and validate our SADA platform in the clinic, with the goal of bringing innovative solutions to patients and value to our shareholders.

ShowHide Related Items >><<
YMAB Y-mAbs Therapeutics
$4.50 /

+0.05 (+1.12%)

YMAB Y-mAbs Therapeutics
$4.50 /

+0.05 (+1.12%)

11/01/22 BMO Capital
Y-mAbs Therapeutics price target lowered to $12 from $29 at BMO Capital
10/31/22 Guggenheim
Y-mAbs Therapeutics price target lowered to $18 from $26 at Guggenheim
10/31/22 Canaccord
Y-mAbs Therapeutics price target lowered to $27 from $35 at Canaccord
10/31/22 Wedbush
Wedbush downgrades Y-mAbs Therapeutics to Neutral, lowers price target to $6
YMAB Y-mAbs Therapeutics
$4.50 /

+0.05 (+1.12%)

YMAB Y-mAbs Therapeutics
$4.50 /

+0.05 (+1.12%)

Hot Stocks
Rigel Pharmaceuticals trading resumes  17:30
12/01/22
12/01
17:30
12/01/22
17:30
RIGL

Rigel Pharmaceuticals

/

+

 
ShowHide Related Items >><<
RIGL Rigel Pharmaceuticals
/

+

RIGL Rigel Pharmaceuticals
/

+

08/18/22 H.C. Wainwright
Rigel Pharmaceuticals price target raised to $15 from $7 at H.C. Wainwright
08/16/22 Piper Sandler
Rigel Pharmaceuticals price target raised to $2 from $1 at Piper Sandler
08/03/22 B. Riley
Rigel Pharmaceuticals price target raised to $1.75 from $1.25 at B. Riley
06/09/22 BMO Capital
Rigel Pharmaceuticals price target lowered to $3 from $7 at BMO Capital
RIGL Rigel Pharmaceuticals
/

+

RIGL Rigel Pharmaceuticals
/

+

Syndicate
Clarivate files to sell 281.67M ordinary shares for holders  17:29
12/01/22
12/01
17:29
12/01/22
17:29
CLVT

Clarivate

$10.05 /

+0.26 (+2.66%)

 
ShowHide Related Items >><<
CLVT Clarivate
$10.05 /

+0.26 (+2.66%)

CLVT Clarivate
$10.05 /

+0.26 (+2.66%)

10/24/22 Jefferies
Clarivate assumed with a Buy at Jefferies
09/28/22 RBC Capital
Clarivate price target lowered to $13 from $16 at RBC Capital
07/12/22 Wells Fargo
Clarivate initiated with an Overweight at Wells Fargo
07/01/22 RBC Capital
Clarivate price target lowered to $18 from $23 at RBC Capital
CLVT Clarivate
$10.05 /

+0.26 (+2.66%)

CLVT Clarivate
$10.05 /

+0.26 (+2.66%)

Hot Stocks
Altimeter Growth Corp 2 trading resumes  17:29
12/01/22
12/01
17:29
12/01/22
17:29
AGCB

Altimeter Growth 2

$10.01 /

-0.005 (-0.05%)

 
ShowHide Related Items >><<
AGCB Altimeter Growth 2
$10.01 /

-0.005 (-0.05%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.